FindTrial
Sign In

Ripasudil

DRUG9 trials

Sponsors

Kowa Research Institute Inc., Mizuno Yu, Stanford University, Kowa Research Institute, Inc., Asociación para Evitar la Ceguera en México

Conditions

Bullous KeratopathyCataractCorneal EdemaCorneal Edema After Cataract SurgeryCorneal Edema PseudophakicCorneal Endothelial DystrophyEndothelial DysfunctionFuchs

Phase 1

Study to Assess Safety and Tolerability of Multiple Doses of EO2002
RecruitingNCT05636579
Asociación para Evitar la Ceguera en MéxicoBullous Keratopathy, Corneal Edema, Corneal Edema Pseudophakic +5
Start: 2022-11-08End: 2025-12-09Target: 12Updated: 2025-12-08

Phase 2

Study on the Safety of Rho-kinase Inhibitor (Ripasudil) with Needling
Active, not recruitingJPRN-jRCTs061220032
Mizuno YuGlaucoma Glaucoma
Start: 2022-08-05Target: 20Updated: 2026-06-29

Phase 3

Descemet Endothelial Thickness Comparison Trial II
RecruitingNCT05275972
Stanford UniversityFuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Start: 2023-01-23End: 2028-10-30Target: 60Updated: 2026-08-17
A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery
CompletedNCT05528172
Kowa Research Institute, Inc.Corneal Edema After Cataract Surgery
Start: 2022-08-04End: 2023-06-22Updated: 2026-09-02
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
CompletedNCT05795699
Kowa Research Institute, Inc.Fuchs Endothelial Corneal Dystrophy
Start: 2023-03-30End: 2026-02-20Updated: 2026-05-27
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
CompletedNCT05826353
Kowa Research Institute, Inc.Fuchs Endothelial Corneal Dystrophy
Start: 2023-05-11End: 2025-10-24Updated: 2026-01-22
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12 Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy
CompletedCTIS2022-502643-35-00
Kowa Research Institute Inc.Fuchs Endothelial Corneal Dystrophy
Start: 2023-08-09End: 2025-10-17Target: 41Updated: 2025-03-21
The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery
RecruitingNCT06048380
Singapore Eye Research InstituteCataract, Fuchs' Endothelial Dystrophy
Start: 2025-03-01End: 2025-07-31Target: 120Updated: 2025-01-29
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy
Active, not recruitingCTIS2024-511752-40-00
Kowa Research Institute Inc.Fuchs Endothelial Corneal Dystrophy
Start: 2023-05-05Target: 27Updated: 2025-03-19

Related Papers

Descemet Endothelial Thickness Comparison Trial II (DETECT II): multicentre, outcome assessor-masked, placebo-controlled trial comparing Descemet membrane endothelial keratoplasty (DMEK) to Descemet stripping only (DSO) with adjunctive ripasudil for Fuchs dystrophy
BMJ Open Ophthalmology2024-10-017 citations